NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 7,505 call options on the company. This is an increase of approximately 962% compared to the typical daily volume of 707 call options.
NewAmsterdam Pharma Stock Down 0.4%
NASDAQ:NAMS traded down $0.07 during trading hours on Tuesday, hitting $19.39. 1,364,098 shares of the stock traded hands, compared to its average volume of 1,207,235. The company has a market cap of $2.33 billion, a price-to-earnings ratio of -11.47 and a beta of 0.15. NewAmsterdam Pharma has a 1 year low of $17.90 and a 1 year high of $42.21. The stock has a 50 day moving average price of $21.41 and a 200 day moving average price of $29.12.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.33. The business had revenue of $19.16 million for the quarter, compared to analysts’ expectations of $8.82 million. NewAmsterdam Pharma had a negative return on equity of 31.39% and a negative net margin of 789.95%. Equities analysts forecast that NewAmsterdam Pharma will post -1.48 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
NAMS has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Sunday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, October 15th. Cantor Fitzgerald lifted their price target on shares of NewAmsterdam Pharma from $52.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 11th. Finally, Royal Bank Of Canada cut their price objective on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, NewAmsterdam Pharma has an average rating of “Moderate Buy” and a consensus target price of $49.82.
Check Out Our Latest Analysis on NewAmsterdam Pharma
Insider Buying and Selling at NewAmsterdam Pharma
In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 125,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00. Following the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. This trade represents a 64.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John W. Smither sold 1,600 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the sale, the director owned 8,760 shares of the company’s stock, valued at approximately $221,803.20. This represents a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 176,846 shares of company stock valued at $4,661,919. 12.74% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in NewAmsterdam Pharma during the first quarter valued at $37,000. Parallel Advisors LLC increased its holdings in shares of NewAmsterdam Pharma by 43.7% in the 3rd quarter. Parallel Advisors LLC now owns 2,012 shares of the company’s stock worth $49,000 after buying an additional 612 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of NewAmsterdam Pharma during the 3rd quarter valued at about $149,000. CenterBook Partners LP bought a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at about $290,000. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of NewAmsterdam Pharma by 147.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company’s stock valued at $292,000 after acquiring an additional 5,437 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.
About NewAmsterdam Pharma
NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.
Featured Stories
- Five stocks we like better than NewAmsterdam Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
